ADRIAN FRANCIS DAVIS,叶德林 法兰西斯 戴维斯,葉德林 法蘭西斯 戴維斯,叶德林 法兰西斯 戴维斯,葉德林 法蘭西斯 戴維斯
申请号：
TW094126897
公开号：
TWI371273B
申请日:
2005.08.09
申请国别(地区):
TW
年份:
2012
代理人:
摘要：
A composition for topical application to a part of the body comprises a vasodilator, for example glyceryl trinitrate, as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the vasodilator. The vasoldator is present in the composition at a concentration at or slightly below saturation, whereby evaporation of the volatile solvent in use will maintain the vasodilator at saturated or super-saturated concentrations in the residue, whereby the vasodilator will become saturated or supersaturated in the solvent remaining and, as the active ingredient passes through the skin and is absorbed in the bloodstream, and thus becomes depleted in the residual composition, continuing evaporation of volatile solvent will maintain the active ingredient substantially at saturation or supersaturation level in the residual composition throughout the major part of the absorption phase, thereby maximising absorption levels but at a moderate dosage level.一種局部應用於身體一部分之醫藥組合物，其係包含一種血管擴張藥，如三硝酸甘油酯，作為有效成分，溶解在對該血管擴張藥具有不同媒合能力之揮發性溶劑與非揮發性溶劑所組成之混合物中。該血管擴張藥在醫藥組合物中為飽和或稍低於飽和，藉助所用之揮發性溶劑之揮發，維持血管擴張藥在剩餘溶劑中之濃度為飽和濃度或過飽和濃度。藉助該血管擴張藥在剩餘溶劑中變成飽和或過飽和，有效成分通過皮膚吸收到血流中，因此在殘餘醫藥組合物中消失。溶劑繼續揮發，在整個吸收階段之主要部分，維持有效成分在剩餘醫藥組合物中實質上處於飽和或過飽和水平，從而以適度之劑量，達到最大之吸收水平。
